News from Monday, January 6, 2024
Articles
Value Viewpoint: January 3, 2025
(1/3, Kimberly Westrich, LinkedIn) comments “...A new article published in Value in Health discusses the growing importance of health economic outcomes research (HEOR) in the valuation of cell and gene therapies (CGTs) in regulatory/economic evaluations and reimbursement strategies. The authors describe five areas in which advances in HEOR have led to a better understanding of the benefits and value of CGTs including: 1. The collection of real-world data (RWD) to generate real-world evidence (RWE), 2. Patient-centricity and novel value assessment frameworks...” Full
Study Finds No Clinical Advantage of Budesonide Inhaler over Fluticasone in COPD
(1/6, Dr. Chinta Sidharthan, News Medical) reports “...The researchers found that dry powder triple inhaler therapy of fluticasone-umeclidinium-vilanterol resulted in fewer COPD exacerbations compared to metered dose triple inhaler therapy of budesonide-glycopyrrolate-formoterol. Among the 20,388 matched pairs, the hazard of a moderate or severe exacerbation was 9% higher for budesonide-glycopyrrolate-formoterol users (hazard ratio 1.09).” Full
Video: Dr Tim Mok: A Pharmacist's Perspective on Balancing Costs and Outcomes
(1/4, Kyle Munz, The American Journal of Managed Care) reports “Tim Mok, PharmD, BCPS, BCOP, malignant hematology pharmacy research analyst at Kaiser Permanente, was the featured moderator of ‘Pharmacy Decision-Making in Value-Based Care,’ a panel conducted at a recent Institute for Value-Based Medicine event in Seattle, Washington. As the panelists explored the intricacies of multidisciplinary collaboration and pharmacy decision making, Mok joined for an interview to discuss his perspective on how to best strike a balance between clinical outcomes and cost considerations. Here, he highlights the value of real-world evidence, prominent challenges in the field, and more.” View Video
Press Releases
Institute for Clinical and Economic Review to Assess Treatments for Spinal Muscular Atrophy
(1/6, ICER Press Release) “The Institute for Clinical and Economic Review announced today that it will assess the comparative clinical effectiveness and value of apitegromab (Scholar Rock) for the treatment of spinal muscular atrophy (SMA). ICER will also assess new evidence (since ICER’s 2019 Final Evidence Report) on the clinical effectiveness of nusinersen (Spinraza®, Biogen) and onasemnogene abeparvovec-xioi (Zolgensma®, Novartis), as well as the evidence for risdiplam (Evrysdi®, Genentech). Risdiplam was not evaluated in the 2019 report.” Full
New Consultation on Additional Improvements to Drug Reimbursement Reviews
(1/6, Canada’s Drug Agency Press Release) “...The consultation document, Proposed Improvements to the Drug Reimbursement Review Process, describes a series of enhancements and new additions to the process we follow to issue drug reimbursement recommendations to public drug plans and cancer agencies (excluding Quebec). This process plays a critical role in the pathway that helps patients access new medicines.” Full
Journals
Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare Diseases
Walter Toro, PhD, et al.
December 30, 2024, Value in Health
Heparin Versus Saline: A Comparative Study to Support Practice Change Within an Organization
Linda Denke, et al.
January/February 2025, Journal of Infusion Nursing
Comparative Overall Survival of CDK4/6 Inhibitors plus an Aromatase Inhibitor in HR+/HER2- Metastatic Breast Cancer in the US Real-World Setting
H S Rugo, et al.
January 3, 2024, ESMO Open
Nonopioid vs Opioid Analgesics after Impacted Third-Molar Extractions: The Opioid Analgesic Reduction Study Randomized Clinical Trial
Cecile A Feldman, et al.
January 4, 2024, Journal of American Dental Association